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ABSTRACT
Introduction: Evolution of antibacterial
resistance in pathogenic enterococcal strains
poses a growing therapeutic challenge.
Daptomycin, a cyclic lipopeptide, exhibits
broad antibiotic activity against Gram-positive
bacteria.
Methods: The European Cubicin Outcomes
Registry and Experience, a multicenter,
retrospective, non-interventional study,
recorded clinical outcomes following
daptomycin treatment.
Results: Overall, 472 patients (predominantly
elderly Caucasian males) were treated for
enterococcal infections. Of those, 72.7%
received antibiotics prior to daptomycin
treatment, whereas 77.1% received other
antibiotics concomitantly. Failure of previous
therapy, resistant or non-susceptible pathogen,
and narrowing of antibiotic therapy were the
main reasons for switching to daptomycin
treatment. Nosocomial infections comprised
55.8% of the cohort. Bacteremia (29.9%),
complicated skin and soft tissue infection
(29.2%) and endocarditis (12.3%) were the
most common primary infections. Clinical
success was achieved in 77.1% of patients, with
similar success rates across all primary infection
categories. The overall clinical success rate was
marginally higher (82.5% vs 74.6%, p = 0.09)
with daptomycin use as first-line versus second-
line therapy. Patients receiving higher doses of
daptomycin exhibited the highest clinical
success rates (85.7% for C8 mg/kg/day vs 75.8%
for \8 mg/kg/day, p = 0.08). While 81 (17.2%)
patients reported at least one adverse event
(AE), only 11 (2.3%) and 3 (0.6%) had
treatment-related AEs and serious AEs,
respectively. Separate microbiologic findings
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from Leipzig University Hospital demonstrate
small proportions of Enterococcus faecium
isolates with daptomycin minimum inhibitory
concentrations = 4 mg/L (4%) or C8 mg/L
(0.8%), which are regarded as non-susceptible.
Conclusion: For enterococcal infections,
daptomycin appears to be an effective and
well-tolerated treatment option, exhibiting
highest clinical success rates at higher doses.
Keywords: Daptomycin; Enterococcal
infections; EU-CORE; Gram-positive infections;
VRE
INTRODUCTION
Enterococci are facultative anaerobic bacteria
tolerant of a wide range of environmental
conditions and constitute normal commensal
flora of the human gastrointestinal tract. Some
species of this genus have a high intrinsic
resistance to antibiotics [1, 2]. In addition, over
the last two decades, particularly virulent strains
of enterococci with acquired resistance to
antibiotics, such as vancomycin, have emerged.
Thus, associated treatment and infection control
have become increasingly difficult [3]. The
constitutive presence of enterococci in
gastrointestinal tracts of hospitalized patients
has assisted the transition from commensal
organisms to nosocomial pathogens and the
evolution of such drug resistance [4, 5].
Moreover, establishment of such multidrug-
resistant pathogens is particularly common
and therapeutically problematic in the hospital
setting [6, 7], and thus constitutes a significant
and growing public health challenge [8, 9].
Enterococci are often encountered in mixed
infections and are particularly found in urinary
tract infections, bacteremia, endocarditis,
diverticulitis, peritonitis, and meningitis [3]. In
recent years, the prevalence of species other
than Enterococcus faecalis has increased.
Particular Enterococcus faecium strains
frequently showing multidrug resistance and
non-susceptibility to vancomycin have
emerged. Few therapeutic options are available
for treating infections caused by vancomycin-
resistant enterococci (VRE) [6].
Daptomycin is a cyclic lipopeptide with
rapid bactericidal activity against a wide range
of Gram-positive bacteria, including multidrug-
resistant enterococci [10–14], and is effective in
inhibiting or disrupting biofilm production
in vitro [15–17]. Its mechanism of action is
distinct from that of other antibiotics, including
b-lactams, aminoglycosides, glycopeptides,
fluoroquinolones, and macrolides. In the
presence of physiological concentrations of
ionized calcium, daptomycin interacts with
the surface of Gram-positive bacteria, leading
to disruption of membrane function [18].
Daptomycin was first approved in 2003, and
is indicated for the treatment of complicated
skin and soft tissue infections (cSSTIs; 4 mg/kg
every 24 h), right-sided endocarditis due to
Staphylococcus aureus and for bacteremia
associated with cSSTI or right-sided
endocarditis (6 mg/kg every 24 h) [19]. It has
been previously shown that daptomycin
(6 mg/kg/day) was highly effective against
susceptible and multidrug-resistant E. faecalis
and E. faecium in vitro and also in a rat model of
experimental endocarditis [20]. Moreover,
treatment with daptomycin in patients with
invasive or bacteremic enterococcal infections
leads to higher frequency of cure (up to 90% or
more) when concomitant and adequate focus
relief was performed [21].
The objective of this sub-analysis from the
European Cubicin Outcomes Registry and
Experience (EU-CORESM) study was to evaluate
the safety and clinical outcome of patients with
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enterococcal infections treated with
daptomycin.
METHODS
Patients and Data Collection
Daptomycin use in a clinical setting frequently
differs from controlled clinical trial or indicated
use. EU-CORE is a retrospective, multicenter,
multinational study conducted across 18
countries—12 in Europe (Austria, Bulgaria,
France, Germany, Greece, Italy, Romania,
Russia, Slovenia, Spain, Turkey, and United
Kingdom), 5 in Latin America (Argentina,
Brazil, Colombia, Mexico, and Venezuela) and
1 in Asia (India). It collected data on patients
receiving daptomycin in a real-world clinical
setting. Patients were enrolled into the study if
they had been treated with at least one dose of
daptomycin and for whom all mandatory
information, as required in the case report
forms, was recorded. Patients received
daptomycin therapy between January 2006
and April 2012 and were followed up for
30 days after the end of treatment. Two-year
follow-up data were collected until 2014 for
patients with endocarditis, intracardiac/
intravascular device infection, osteomyelitis,
or orthopedic device infection. A written
informed consent was obtained when required
by the Institutional Review Board/Ethical
Committee and/or local data privacy
regulations. Patients who received daptomycin
as part of a controlled clinical trial were not
eligible for inclusion in the study. Interim
results of the EU-CORE registry were
previously reported [22, 23].
A standardized case report form and protocol
were used to collect demographic and clinical
information on patients who had been treated
with daptomycin. Demographic, antibiotic,
microbiologic, and clinical data were collected
from medical records at each site. Data
collection was carried out as previously
described by Gonzalez-Ruiz et al. [19].
Clinical Outcomes and Safety
Investigators assessed the clinical outcome at
the end of daptomycin therapy according to the
following protocol-defined criteria: cured,
clinical signs and symptoms resolved, no
additional antibiotic therapy was necessary, or
infection cleared with a negative culture
reported; improved, partial resolution of
clinical signs and symptoms and/or additional
antibiotic therapy was warranted; failed,
inadequate response to daptomycin therapy,
worsening or new/recurrent signs and
symptoms, need for a change in antibiotic
therapy, or a positive culture reported at the
end of therapy; and non-evaluable, unable to
determine response due to insufficient
information [24].
Clinical success was used to collectively
describe patients with an outcome of cured or
improved. Time to improvement was also
recorded. Duration of treatment was measured
as the number of inpatient and outpatient days
during which the patient received daptomycin
therapy, even if these were non-consecutive.
There were no restrictions on concomitant
treatment in the EU-CORE study. The safety
population comprised all eligible patients who
had any safety parameters assessed, and the
efficacy population comprised all eligible
patients for whom clinical outcome was
assessed. Safety was assessed for up to 30 days
after the end of daptomycin treatment.
All reported deaths, adverse events (AEs) and
serious AEs (SAEs), regardless of their
relationship to daptomycin, were recorded,
and the severity of AEs was determined.
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Microbiology
For the EU-CORE study, antibiotic susceptibility
profiles based on testing performed at the local
laboratories were listed for each bacterial
species. Antibiograms were analyzed through
tabulations of susceptibility classifications
(defined as susceptible/intermediate/resistant)
based on the susceptibility breakpoints used by
the local laboratory and minimum inhibitory
concentration (MIC) values when available.
For all enterococcal isolates from the Leipzig
University Hospital, Germany, MICs were
determined using the ISO 20776-1 (http://
www.iso.org) microbroth dilution method.
Susceptibilities were assessed using breakpoints
established by the Clinical Laboratory Standards
Institute (CLSI; http://www.clsi.org). The cur-
rent CLSI susceptibility breakpoint for dapto-
mycin is B4 mg/L. In view of the limited clinical
data available, the European Committee on
Antimicrobial Susceptibility Testing (EUCAST;
http://www.eucast.org) has published the epi-
demiological cutoff values of 4 mg/L for both
E. faecalis and E. faecium.
Statistical Analysis
Statistical analysis was performed using SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Numerical variables were summarized as
arithmetic mean, standard deviation, median,
minimum, first quartile, third quartile, and
maximum for continuous variables.
Categorical variables were summarized by
absolute and relative frequencies, and missing
values were not included in the calculation of
relative frequencies. Categorical data were
analyzed by the Chi-square or Fisher’s exact
test and p values (two-tailed) of\0.05 were
considered to be statistically significant.
RESULTS
Patient Demographic and Clinical
Characteristics
Of the 6075 patients (5467 from Europe, 409
from Latin America and 199 from Asia) enrolled
in the EU-CORE study, 472 (7.8%) patients had
enterococcal infections as the primary
diagnosis. All were included in both the safety
and efficacy populations (Table 1).
Patients were predominantly adults with a
median age of 65 (range 1–94) years and a
median body weight of 75 (range 6–177) kg.
The majority were male (63.3%) and
Caucasian (87.7%; Table 1). Comorbidity was
frequent, as would be expected in patients
with invasive enterococcal infections.
Cardiovascular disease was the most common
underlying disease, reported in 55.9% of the
cohort, followed by diabetes mellitus (27.8%),
renal disease (22.0%), gastrointestinal disease
(21.0%), cancer (19.5%), and pulmonary
disease (13.6%).
Of the 163 patients for whom data were
available, 91 (55.8%) patients acquired
nosocomial infections, 63 (38.7%) patients
acquired infection in a community setting,
and 9 (5.5%) patients in a nursing home/
extended care setting.
Primary Infections
Of the wide range of primary infection types
treated with daptomycin, bacteremia (29.9%),
cSSTI (29.2%) and endocarditis (12.3%) were
the most common (Table 2). Patients with
foreign body/prosthetic infection (8.5%),
urinary tract infection/pyelonephritis (4.7%),
osteomyelitis (4.4%), and infections classified
as other (11%) were also enrolled.
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Previous and Concomitant Antibiotic
Therapies
Of the 472 patients, 343 (72.7%) patients
received antibiotics prior to daptomycin
therapy. While 152 (32.2%) patients received
penicillins, 132 (28.0%) received glycopeptides
(of whom 93 [19.7%] were administered
vancomycin as a prior therapy). Furthermore,
108 (22.9%) patients received carbapenems and
91 (19.3%) patients received cephalosporins.
The main reasons for switching to
daptomycin were failure of previous antibiotic
therapy (32.6%), a resistant or non-susceptible
pathogen (14.4%), toxicity/intolerance (8.7%),
and narrowing of antibiotic therapy (8.1%).
Concomitant antibiotic therapy with
daptomycin was received by 357 (77.1%)
inpatients; carbapenems (35.4%), b-lactams
(26.9%), and fluoroquinolones (11.7%) were
the most frequently used concomitant
antibiotics.
Daptomycin Prescribing Patterns
The most commonly prescribed dose of
daptomycin was 6 mg/kg/day (47.0%), and
20.1% of patients received [6 mg/kg/day
(Table 3). A dose of [6 mg/kg/day was most
frequently administered in endocarditis,
osteomyelitis and foreign body/prosthetic
infection. The median duration of daptomycin
therapy was 12 (range 1–83) days for inpatients
(n = 461) and 19 (range 3–68) days for
outpatients (n = 36).
Clinical Outcomes
Overall clinical success rate was 77.1%. Notably,
only 7.2% of patients were documented as
having failed treatment and 15.7% of patients
were non-evaluable. Rates of clinical success
across different infections and infecting
enterococcal pathogens are shown in Figs. 1
and 2, respectively. The overall clinical success
rate for different infections was slightly higher
Table 1 Demographic and clinical characteristics
Characteristics N5 472
Age (years), median (range) 65 (1–94)
Age (years), n (%)
\65 (including\18) 236 (50.0)
\18 5 (1.1)






Body weight (kg), median (range) 75 (6–177)
Frequent signiﬁcant underlying disease, n (%)
Cardiovascular disease 264 (55.9)
Diabetes mellitus 131 (27.8)
Renal disease 104 (22.0)
Gastrointestinal disease 99 (21.0)
Malignancy 92 (19.5)
Pulmonary disease 64 (13.6)
Renal function, n (%)
Creatinine clearance\30 mL/min 68 (14.8)
Setting prior to onset of infection, n (%)a
Hospital 91 (55.8)
Nursing home/extended care 9 (5.5)
Community 63 (38.7)
Unknown 309
a Denominators of different settings excluded patients
with unknown information
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Bacteremia 141 (29.9) 20 (14.2) 77 (54.6) 22 (15.6) 12 (8.5) 22 (15.6)
Complicated skin and soft tissue
infection
138 (29.2) 54 (39.1) 50 (36.2) 20 (14.5) 13 (9.4) 14 (10.1)
Endocarditis 58 (12.3) 1 (1.7) 32 (55.2) 23 (39.7) 15 (25.9) 2 (3.4)
Foreign body/prosthetic infection 40 (8.5) 3 (7.5) 19 (47.5) 15 (37.5) 12 (30.0) 3 (7.5)
Urinary tract infection/pyelonephritis 22 (4.7) 13 (59.1) 8 (36.4) 1 (4.5) 0 (0) 0 (0)
Osteomyelitis 21 (4.4) 3 (14.3) 9 (42.9) 8 (38.1) 6 (28.6) 1 (4.8)
Otherc 52 (11.0) 9 (17.3) 27 (51.9) 6 (11.5) 5 (9.6) 10 (19.2)
Total 472 (100.0) 103 (21.8) 222 (47.0) 95 (20.1) 63 (13.3) 52 (11.0)
a Includes C8 mg/kg/day
b Includes[4 to\6 mg/kg/day,\4 mg/kg/day and unknown
c Includes uncomplicated skin and soft tissue infection, necrotizing infections, central nervous system infection, surgical/
non-surgical antibiotic prophylaxis, metastatic abscess, septic arthritis, or not otherwise speciﬁed













Bacteremia 141 (29.9) 58 (41.1) 72 (51.1) 11 (7.8)
Complicated skin and soft tissue
infection
138 (29.2) 71 (51.4) 54 (39.1) 13 (9.4)
Endocarditis 58 (12.3) 43 (74.1) 8 (13.8) 7 (12.1)
Foreign body/prosthetic infection 40 (8.5) 27 (67.5) 9 (22.5) 4 (10.0)
Urinary tract infection/pyelonephritis 22 (4.7) 7 (31.8) 10 (45.5) 5 (22.7)
Osteomyelitis 21 (4.4) 14 (66.7) 6 (28.6) 1 (4.8)
Othera 52 (11.0) 16 (30.8) 25 (48.1) 11 (21.2)
Total 472 (100.0) 236b (50.0) 184c (39.0) 52 (11.0)
a Includes uncomplicated skin and soft tissue infection, necrotizing infections, central nervous system infection, surgical/
non-surgical antibiotic prophylaxis, metastatic abscess, septic arthritis, or not otherwise speciﬁed
b Vancomycin-resistant E. faecalis = 18/236 (3.8%): three bacteremia, six complicated skin and soft tissue infection, three
foreign body/prosthetic infection, two urinary tract infection/pyelonephritis, three osteomyelitis, and one other
c Vancomycin-resistant E. faecium = 46/184 (9.7%): 25 bacteremia, nine complicated skin and soft tissue infection, three
endocarditis, three foreign body/prosthetic infection, two urinary tract infection/pyelonephritis, and four other
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when daptomycin was used as first-line (82.5%)
than second-line (74.6%) therapy (p = 0.09).
The clinical success rate by infection type
independent of the treatment dose ranged
between 69.2% and 83.3%. The clinical success
rate for cSSTI was 83.3%, endocarditis 82.8%,
urinary tract infection/pyelonephritis 81.8%,
bacteremia 73.0%, foreign body/prosthetic
infection 72.5%, and osteomyelitis 71.4%
(Fig. 1). Clinical success rates were overall
similar for doses \8 mg/kg/day (75.8%), but
were higher in patients treated with doses
C8 mg/kg/day (85.7%, p = 0.08). The median
time to improvement was 4 (range 1–30) days
from initiation of daptomycin treatment.
Overall, clinical success rates were similar
whether patients received no concomitant
antibiotic therapy (78.0%) or any concomitant
antibiotic therapy (77.3%).
Microbiology
On the basis of the reported percentage of
susceptible isolates, daptomycin was more
active than vancomycin against E. faecalis
(94.9% vs 89.1%), E. faecium (96.9% vs 66.2%),
and Enterococcus species (83.3% vs 56.4%;
Table 4).
Susceptibility data of enterococci to
daptomycin stating the exact MICs were not
available from the EU-CORE registry. To address
this issue, the MIC determinations for
daptomycin for primary isolates of E. faecalis
and E. faecium strains detected in clinical
specimens at the Leipzig University Hospital,
Germany, in 2014 were analyzed (Fig. 3).
Displaying the expected Gaussian distribution
curve, the data showed only small proportions
of E. faecalis and E. faecium isolates with
daptomycin MICs = 4 mg/L (1.9% and 4%,
respectively) or C8 mg/L (1.3% and 0.8%,
respectively). Among these E. faecalis and
E. faecium isolates, the VRE rate was 0.8% and
36.2%, respectively. Using the current CLSI
susceptibility breakpoint for daptomycin
(B4 mg/L), resistance rates of 1.3% for
E. faecalis and 0.8% for E. faecium need to be
considered.
Fig. 1 Clinical outcome by primary infection type. cSSTI complicated skin and soft tissue infection, UTI urinary tract
infection
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Safety
A total of 81 (17.2%) patients reported at least
one AE and 63 (13.3%) reported SAEs. The most
common AEs ([1% patients) are listed in
Table 5. Most AEs and SAEs were considered as
unrelated to daptomycin treatment by the
investigator, with 11 (2.3%) and 3 (0.6%)
treatment-related AEs and SAEs, respectively,
being recorded. A total of 46 (9.7%) patients
died during the study or follow-up (Table 5).
The main causes of death were multi-organ
failure, sepsis and septic shock. Discontinuation
of daptomycin treatment due to an AE occurred
in 6.1% of patients. There were a total of five
patients with rhabdomyolysis AEs and SAEs, of
whom three were considered by the investigator
as possibly treatment related (two AEs and one
SAE). Of the patients with treatment-related
rhabdomyolysis, two discontinued the study.
Fig. 2 Clinical outcome by primary infecting enterococcal pathogen









Enterococcus faecalis Daptomycin 99 94 (94.9) – 3 (3.0)
Vancomycin 201 179 (89.1) 2 (1.0) 18 (9.0)
Enterococcus faecium Daptomycin 65 63 (96.9) 1 (1.5) –
Vancomycin 154 102 (66.2) – 46 (29.9)
Enterococcus species Daptomycin 18 15 (83.3) 1 (5.6) 1 (5.6)
Vancomycin 39 22 (56.4) 3 (7.7) 14 (35.9)
Susceptibility data of isolates from some patients were missing
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No AEs of eosinophilic pneumonia were
reported.
Serum creatine phosphokinase (CPK) was
measured at baseline for 293 patients, and the
majority (85.0%) had normal values. At
baseline, four (1.4%) patients had CPK levels
[109 upper limit of normal (ULN). Eight
patients had a shift of CPK elevation
from B109 ULN at baseline to [109 ULN.
Increased blood CPK was reported as an AE in
five (1.1%) patients and as an SAE in one (0.2%)
patient.
DISCUSSION
The EU-CORE study illustrates real-world usage
of daptomycin in the treatment of enterococcal
infections. The many multinational sites
enrolled in the EU-CORE study allowed a wide
spectrum of patients. Overall, treatment of
enterococcal infections with daptomycin was
associated with high rates of clinical success.
Daptomycin showed good effectiveness
whether used as first- or second-line therapy.
Available interventions for VRE are mostly
based on expert opinion recommendations [25].
A recent meta-analysis has showed that the two
most commonly prescribed drugs, daptomycin
and linezolid, were equally efficacious in blood
stream infections due to VRE [26]. A 2-year
retrospective study conducted at the Detroit
Medical Center also showed that daptomycin
was as efficacious as linezolid and b-lactams in
Fig. 3 Daptomycin susceptibility of enterococci—Leipzig University Hospital, Germany, January to December 2014
Table 5 Safety of daptomycin treatment
Safety parameters N5 472
n (%)
Deaths 46 (9.7)
Serious adverse events 63 (13.3)
Adverse events 81 (17.2)
Adverse events leading to permanent drug
discontinuation
29 (6.1)
Adverse events occurring in[1% of patients
Multi-organ failure 12 (2.5)
Septic shock 10 (2.1)
Sepsis 9 (1.9)
Blood creatine phosphokinase increased 5 (1.1)
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treating bacteremia due to VRE [27]. However,
prolonged linezolid treatment has been
associated with multiple safety concerns [28,
29].
Daptomycin has previously been shown to
be active against Enterococcus species with
vancomycin non-susceptible E. faecalis and
E. faecium being 100.0% and 99.8% susceptible
to daptomycin, respectively [30]. In the current
study, daptomycin was reported as
microbiologically more active than
vancomycin against Enterococcus species.
Although licensed differently, many
clinicians recommend daptomycin at a higher
dose of 8–10 mg/kg/day for complicated
bacteremia and native valve endocarditis [31].
Kullar et al. assessed the clinical and
microbiologic outcomes of high-dose
daptomycin therapy and reported that
daptomycin doses of C8 mg/kg/day may be
safe and effective in patients with complicated
Gram-positive infections (including
Enterococcus species) [32]. In the EU-CORE
study, high-dose treatment resulted in a
marginally higher overall clinical success rate
(85.7% for doses C8 mg/kg/day compared with
75.8% for doses\8 mg/kg/day). As daptomycin
MICs for Enterococcus species are typically
higher than those for other Gram-positive
organisms (0.5–4 vs 0.25–1 mg/L), patients
with these serious infections may require
higher doses of daptomycin for optimal
treatment.
Recent microbiologic findings from the
Leipzig University Hospital, Germany, which
are not included in the EU-CORE data,
demonstrate only small proportions of
E. faecalis and E. faecium isolates with
daptomycin MICs = 4 mg/L or C8 mg/L
(Fig. 3). Among these E. faecalis and E. faecium
isolates, the VRE rate was 0.8% and 36.2%,
respectively. Using the current CLSI
susceptibility breakpoint for daptomycin
(B4 mg/L), resistance rates of 1.3% for
E. faecalis and 0.8% for E. faecium need to be
considered. Previously, it was reported that
high-dose ([6 mg/kg/day; median dose,
8.2 mg/kg/day) daptomycin treatment of
enterococcal infections with MICs B4 mg/L
was associated with high clinical success
(81–100%), whereas treatment was
unsuccessful with high daptomycin MIC
(C8 mg/L) [33]. Thus, high clinical cure rates
would generally be expected when adequate
concomitant source control is performed and
when suggested MIC limits are respected.
The rates of AEs reported in this retrospective
observational study were low and should not be
compared to AE reporting during a randomized
clinical trial. Daptomycin had generally a
favorable safety profile with no new or
unexpected safety findings in this population.
SAEs and deaths were reflective of the severity of
underlying infections and health status of
patients.
These results complement data from
randomized clinical studies [34] and show that
daptomycin is a valuable treatment option in
the management of enterococcal infections,
especially with rising rates of multidrug-
resistant enterococci exhibiting resistance to
standard enterococcal antibiotics (i.e.,
ampicillin, vancomycin and aminoglycosides).
There are limitations to this retrospective
analysis of the EU-CORE registry data. First, it
does not allow comparison of treatments as in a
randomized trial. In addition, while prior and
concomitant use of other antibiotic agents as
well as presence of mixed infections were
documented, this was not controlled and
might have complicated the interpretation of
clinical outcome. No blinding or independent
evaluations were incorporated and patient
outcomes were solely determined by the
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treating physician. Furthermore, disease
severity was not accounted for in the analysis,
and patient selection bias could not be
discounted. However, variability in dosing and
patient population reflects the real-world
clinical setting for daptomycin use (i.e.,
treatment of diverse infections and
concomitant use of antibiotics). It also
provides a valuable insight into the real-world
clinical practice (often sicker patients than
those enrolled in clinical trials) and expands
on the outcomes derived from the existing
clinical trials.
CONCLUSIONS
Currently, there is not much comprehensive
work published regarding optimal antibiotic
selection for the treatment of VRE infections.
Studies described in the literature are limited by
small sample sizes, lack of patient-level data and
inconsistent outcomes definitions. However,
the data obtained in the EU-CORE study
described here are encouraging and indicate a
benefit of high-dose therapy. Future
investigation, including randomized clinical
trials adjusted to measured MIC levels, is
warranted to support guidance for therapeutic
regimens for VRE infections.
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